An experimental vaccine for kidney cancer is off to a promising start. In data from a Phase I trial released this week, the ...

In a Phase 1 study, nine people with advanced kidney cancer became cancer free after receiving personalized vaccines.

EVAX READ THE FULL EVAX RESEARCH REPORT Evaxion (NASDAQ:EVAX) is a clinical stage company that is making AI useful in the current environment by using the technology to develop new cancer-fighting ...

The fusion of mRNA technology with AI has laid the foundation for ushering in a new era of cancer care. However, conducting ...

The proposed guidance aims to provide a framework for the approval of personalised mRNA-based cancer vaccines.

Harnessing AI to Revolutionize Vaccine and Therapy Development ATLANTA, GA - (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX ...

WASHINGTON – Facing intense scrutiny from senators over his potential profit from vaccine lawsuits while serving as the ...

The man who hopes to be President Donald Trump’s health secretary says he needs to see data showing vaccines are safe, but he ...

The latest guidance reduction was the second time in the last six months that the firm has revised its forecast in a negative ...

An exciting collaboration between the Ragon Institute and the Jameel Clinic at MIT has achieved a significant milestone in leveraging artificial intelligence (AI) to aid the development of T cell ...